BioCentury | Jan 19, 2015
Clinical News

Testosterone undecanoate: Phase IIb data

...with no patient having a Cmax of >1,800 ng/dL. No serious adverse events were reported. SOV Therapeutics Inc....
Items per page:
1 - 1 of 1
BioCentury | Jan 19, 2015
Clinical News

Testosterone undecanoate: Phase IIb data

...with no patient having a Cmax of >1,800 ng/dL. No serious adverse events were reported. SOV Therapeutics Inc....
Items per page:
1 - 1 of 1